Next Article in Journal
Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial
Next Article in Special Issue
Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation
Previous Article in Journal
Influence of Intratumor Microbiome on Clinical Outcome and Immune Processes in Prostate Cancer
Previous Article in Special Issue
Interleukin-1β and Cancer
Commentary

Relevant Cytokines in the B Cell Lymphoma Micro-Environment

1
Department I of Internal Medicine, University of Cologne, Kerpener Str. 62, 50937 Köln, Germany
2
Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Joseph-Stelzmann-Str. 26, 50931 Cologne, Germany
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(9), 2525; https://doi.org/10.3390/cancers12092525
Received: 3 July 2020 / Revised: 22 July 2020 / Accepted: 2 September 2020 / Published: 5 September 2020
(This article belongs to the Special Issue Interleukin in Cancer Pathogenesis and Treatment)
Cytokines are soluble protein factors with importance in intercellular communication and, as such, play pivotal roles in the pathogenesis of B cell malignancies. Evidence from in vitro cultures permitted us to choose example cytokines that bind to different biochemical receptor types. Activated malignant B cells or stromal fibroblasts and macrophages prominently secrete the chemokines CCL3 or CXCL12 and CXCL13, respectively. Apart from helper T cells, various cell types of the B cell lymphoma microenvironment are capable of producing the cytokines IL-4, IL-6, IL-10 and TNFα. Owing to its impact on the development of myeloid cells, CSF-1 is among important soluble factors in the B cell lymphoma microenvironment. Inhibitors of B cell receptor-associated kinases often act via the blockade of cytokine production, but also prevent cytokine effects, e.g., chemotaxis. Increments in blood levels in chronic lymphocytic leukemia patients compared to healthy donors and normalization upon treatment with ibrutinib can be explained by producing cell types and modulation of cytokine production observed in vitro. View Full-Text
Keywords: chronic lymphocytic leukemia; T cells; lymphoma-associated macrophages; chemokines; B cell receptor; B cell receptor-associated kinases; PI3K; BTK; idelalisib; ibrutinib chronic lymphocytic leukemia; T cells; lymphoma-associated macrophages; chemokines; B cell receptor; B cell receptor-associated kinases; PI3K; BTK; idelalisib; ibrutinib
MDPI and ACS Style

Krause, G.; Hassenrück, F.; Hallek, M. Relevant Cytokines in the B Cell Lymphoma Micro-Environment. Cancers 2020, 12, 2525. https://doi.org/10.3390/cancers12092525

AMA Style

Krause G, Hassenrück F, Hallek M. Relevant Cytokines in the B Cell Lymphoma Micro-Environment. Cancers. 2020; 12(9):2525. https://doi.org/10.3390/cancers12092525

Chicago/Turabian Style

Krause, Günter, Floyd Hassenrück, and Michael Hallek. 2020. "Relevant Cytokines in the B Cell Lymphoma Micro-Environment" Cancers 12, no. 9: 2525. https://doi.org/10.3390/cancers12092525

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop